NAS
UTHR icon

Nykredit A/S’s United Therapeutics UTHR Stock Holding History

Nykredit A/S’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.78M Buy
+14,350
New +$8.08M 0.03% 403

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Nykredit A/S's UTHR Position: Q2 2026 in Review

Nykredit A/S opened a new position in United Therapeutics (UTHR) in Q2 2026: 14,350 shares worth $7.78M. The stake represents 0.03% of the portfolio and ranks #403 among its holdings.

884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Nykredit A/S held 14,350 shares of United Therapeutics worth $7.78M as of Q2 2026.
  • United Therapeutics was a new Nykredit A/S position in Q2 2026.
  • United Therapeutics made up 0.03% of Nykredit A/S's portfolio in Q2 2026, its #403 holding.
  • 884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.